Select Page

About Theragenics brachytherapy

About

Continuing To Do More To Save More Lives

A global leader in the manufacture of radioactive brachytherapy seeds for the treatment of localized prostate cancer.

Theragenics was founded in 1981 and quickly became a global leader in the manufacture of radioactive brachytherapy seeds for the treatment of localized prostate cancer. We began diversifying operations in 2005 by acquiring CP Medical, Inc., and have continued to expand with the acquisitions of Galt Medical Corp., NeedleTech Products, Inc., Concert Medical, and Arrotek.

In the early years, the company’s strategy was to identify those cancers whose cure rates had not improved significantly in the previous two decades, that were consistently diagnosed as inoperable, or that had claimed increasingly more lives – then to develop products to treat those cancers. Theragenics developed TheraSeed®, a rice-sized titanium-encapsulated device based on the palladium-103 radioactive isotope, which is implanted percutaneously using ultrasound guidance. While radioactive iodine-125 and other isotopes had been used for over 20 years, Theragenics researchers believed palladium-103 to be a desirable alternative to iodine-125 because of a much shorter half-life and higher initial dose rate.

Today, Theragenics brachytherapy seed products for treatment of early stage prostate cancer are sold in several countries and regions around the world, including the United States, EU, Japan, Canada, the United Kingdom, Ireland, Portugal, Australia, New Zealand, Thailand, and Singapore. It’s estimated that Theragenics’ TheraSeed® and AGX100® seed products have been used to treat over 240,000 men.

Previously, Theragenics performed research and development related to cancers other than prostate, as well as non-cancer diseases. While these development programs are no longer taking place, certain technologies and intellectual property that were developed are still used today. Since the early 1990’s TheraSeed® has been used as an alternative to enucleation for treating ocular melanoma, and today both TheraSeed® and AGX100® are available for eye plaque implants to treat this disease.

Through acquisitions and organic achievements, Theragenics continues to diversify and expand its capabilities and product offerings to address needs across multiple markets, including but not limited to, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery.

Radiation Oncology

An industry pioneer and leader, Theragenics has an unparalleled history of more than 35 years in the manufacture, global supply and distribution of low-dose rate (LDR) brachytherapy seeds for the treatment of prostate cancer, intra-ocular malignancies, and other tumor types with radiosensitivity. We continue to invest and develop innovative brachytherapy solutions to better serve physicians and their patients.

Content intended for the USA & EU. Indications may vary in different countries; please either consult the appropriate IFU or your local distributor.

Interventional Solutions

With over 3 decades of expertise designing, developing, manufacturing and marketing disposable medical devices, Theragenics Interventional is a leading global provider of vascular and other access products for a diverse range of interventional procedures. Recognized for high quality precision design, our devices are trusted for their robustness and reliability.

Wound CLosure

CP Medical (a wholly-owned subsidiary of Theragenics) is a leading manufacturer of surgical solutions, specializing in products for wound closure and specialty surgical applications in the medical and veterinary markets.

Connect with us

Whether you’re an experienced clinician or seeking a more patient-friendly solution, we’re here to help!

Send us an email to learn how Theragenics brachytherapy can empower your clinical practice.

13 + 1 =